Purchase Agreement, dated October 11, 2011



 Exhibit 10.1 
 EXECUTION COPY 
 PURCHASE AGREEMENT 

PURCHASE AGREEMENT (the “Agreement”), dated as of October 11, 2011, by and between MARINA BIOTECH,
INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). 

WHEREAS: 
 Subject to the
terms and conditions set forth in this Agreement, the Company has the right to sell to the Investor, and the Investor has the obligation to buy from the Company, up to Fifteen Million Dollars ($15,000,000) of the Company’s common stock, $.006
par value per share (the “Common Stock”). The shares of Common Stock to be purchased hereunder are referred to herein as the “Purchase Shares.” 
 NOW THEREFORE, the Company and the Investor hereby agree as follows: 
  

	 	1.	CERTAIN DEFINITIONS. 

 For
purposes of this Agreement, the following terms shall have the following meanings: 
 (a) “Accelerated Purchase
Notice” shall mean an irrevocable written notice from the Company to the Investor directing the Investor to buy such Accelerated Purchase Amount in Purchase Shares as specified by the Company therein on the Purchase Date. 

(b) “Available Amount” means initially Fifteen Million Dollars ($15,000,000) in the aggregate which amount shall be
reduced by the Purchase Amount each time the Investor purchases shares of Common Stock pursuant to Section 2 hereof. 
 (c)
“Bankruptcy Law” means Title 11, U.S. Code, or any similar federal or state law for the relief of debtors. 

(d) “Business Day” means any day on which the Principal Market is open for trading including any day on which the
Principal Market is open for trading for a period of time less than the customary time. 
 (e) “Closing Sale
Price” means, for any security as of any date, the last closing sale price for such security on the Principal Market as reported by the Principal Market, or, if the Principal Market is not the principal securities exchange or trading market
for such security, the last closing sale price of such security on the principal securities exchange or trading market where such security is listed or traded as reported by the Principal Market. 

(f) “Confidential Information” means any information disclosed by either party to the other party, either directly or
indirectly, in writing, orally or by inspection of tangible objects (including, without limitation, documents, prototypes, samples, plant and equipment), which is designated as “Confidential,” “Proprietary” or some similar
designation. Information communicated orally shall be considered Confidential Information if such information is confirmed in writing as being Confidential Information within ten (10) Business Days after the initial disclosure. Confidential
Information may also include information disclosed to a disclosing party by third parties. Confidential Information shall not, however, include any information which (i) was publicly known and made generally available in the public domain prior
to the time of disclosure by the disclosing party; (ii) becomes publicly known and 







 
made generally available after disclosure by the disclosing party to the receiving party through no action or inaction of the receiving party; (iii) is already in the possession of the
receiving party at the time of disclosure by the disclosing party as shown by the receiving party’s files and records immediately prior to the time of disclosure; (iv) is obtained by the receiving party from a third party without a breach
of such third party’s obligations of confidentiality; (v) is independently developed by the receiving party without use of or reference to the disclosing party’s Confidential Information, as shown by documents and other competent
evidence in the receiving party’s possession; or (vi) is required by law to be disclosed by the receiving party, provided that the receiving party gives the disclosing party prompt written notice of such requirement prior to such
disclosure and assistance in obtaining an order protecting the information from public disclosure. 
 (g)
“Custodian” means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law. 

(h) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

(i) “Expense Shares” means 50,000 shares of duly authorized, validly issued, fully paid and nonassessable shares of
Common Stock, which the Company heretofore has caused its transfer agent to issue and deliver to the Investor. 
 (j)
“Maturity Date” means the date that is 600 Business Days (30 Monthly Periods) from the Commencement Date. 

(k) “Monthly Period” means each successive 20 Business Day period commencing with the Commencement Date. 

(l) “Person” means an individual or entity including but not limited to any limited liability company, a partnership, a
joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency thereof. 

(m) “Principal Market” means the NASDAQ Global Market; provided however, that in the event the Company’s Common
Stock is ever listed or traded on the NASDAQ Capital Market, the NASDAQ Global Select Market, the New York Stock Exchange, the NYSE Amex, or the OTC Bulletin Board (it being understood that as used herein “OTC Bulletin Board” shall also
mean any successor or comparable market quotation system or exchange to the OTC Bulletin Board such as the OTCQB operated by the OTC Markets Group, Inc.), then the “Principal Market” shall mean such other market or exchange on which the
Company’s Common Stock is then listed or traded. 
 (n) “Purchase Amount” means, with respect to any
particular purchase made hereunder, the number of shares to be purchased by the Investor pursuant to Section 2 hereof multiplied by the Purchase Price. 
 (o) “Purchase Date” means with respect to any particular purchase made hereunder, the Business Day on which the Investor receives by 10:00 a.m. eastern time of such Business Day a valid
Purchase Notice or Accelerated Purchase Notice that the Investor is to buy Purchase Shares pursuant to Section 2 hereof. 

(p) “Purchase Price” means the lower of the (A) the lowest Sale Price of the Common Stock on the Purchase Date and
(B) the arithmetic average of the three (3) lowest Closing Sale Prices for the Common Stock during the twelve (12) consecutive Business Days ending on the Business Day immediately preceding such Purchase Date (to be appropriately
adjusted for any reorganization, 

  
 -2-









 
recapitalization, non-cash dividend, stock split or other similar transaction), which number shall be rounded to the nearest one-tenth (1/10) of a cent. 

(q) “Purchase Notice” shall mean a written notice from the Company to the Investor directing the Investor to buy such
Purchase Amount in Purchase Shares as specified by the Company therein on the Purchase Date. 
 (r) “Sale
Price” means any sale price for the shares of Common Stock on the Principal Market as reported by the Principal Market. 
 (s) “SEC” means the United States Securities and Exchange Commission. 
 (t) “Securities Act” means the Securities Act of 1933, as amended. 
 (u) “Signing Price” means $0.169, representing the book value per share of Common Stock as of October 10, 2011, calculated in accordance with the rules of the NASDAQ Stock Market.

 (v) “Transfer Agent” means the transfer agent of the Company as set forth in Section 11(f) hereof or
such other person who is then serving as the transfer agent for the Company in respect of the Common Stock. 
  

	 	2.	PURCHASE OF COMMON STOCK. 


Subject to the terms and conditions set forth in this Agreement, the Company has the right to sell to the Investor, and the Investor has
the obligation to purchase from the Company, Purchase Shares as follows: 
 (a) Purchases. Within one (1) Business
Day following the satisfaction of the conditions (the “Commencement”) as set forth in Sections 7 and 8 below (the date of satisfaction of such conditions, the “Commencement Date”), the Company shall have the right
but not the obligation on each Business Day during the term of this Agreement to direct the Investor by its delivery to the Investor of a Purchase Notice from time to time to buy up to 300,000 shares of common stock (each such purchase a
“Regular Purchase” and each such shares “Purchase Shares”) at the Purchase Price on the Purchase Date. The Regular Purchase may be increased to up to 400,000 Purchase Shares per Purchase Notice (each such purchase a
(“Tier 1 Purchase”) if the Closing Sale Price of the Common Stock is not below $0.30 (subject to equitable adjustment for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction) (the
“Tier 1 Threshold”) on the Purchase Date. The Regular Purchase may be increased to up to 500,000 Purchase Shares per Purchase Notice (each such purchase a (“Tier 2 Purchase”) if the Closing Sale Price of the Common
Stock is not below $0.40 (subject to equitable adjustment for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction) (the “Tier 2 Threshold”) on the Purchase Date. With respect to each
such Regular Purchase, Tier 1 Purchase and Tier 2 Purchase, as applicable, the Company must deliver the Purchase Shares before 1:00 p.m. eastern time on the Business Day following the Purchase Date. If on any Purchase Date the Closing Sale Price of
the Common Stock is (w) for a Tier 1 Purchase, below the Tier 1 Threshold or (x) for a Tier 2 Purchase, below the Tier 2 Threshold, then the number of Purchase Shares shall automatically be reduced to (y) a Regular Purchase in the
case of a Purchase Notice delivered for a Tier 1 Purchase and (z) a Tier 1 Purchase in the case of Purchase Notice delivered for a Tier 2 Purchase. The Company may deliver a Purchase Notice to the Investor each Business day during the term of
this Agreement. 

  
 -3-









 (b) Accelerated Purchases. At any time after the Commencement Date, the Company shall
also have the right to direct the Investor to buy up to 400,000 Purchase Shares (each such purchase an “Accelerated Purchase” and the amount so purchased the “Accelerated Purchase Amount”) per Accelerated Purchase
Notice at the Accelerated Purchase Price on the Purchase Date by delivering to the Investor Accelerated Purchase Notices provided that the Closing Sale Price of the Common Stock must not be below $.10 (subject to equitable adjustment for any
reorganization, recapitalization, non-cash dividend, stock split or other similar transaction) on the Purchase Date (the “Accelerated Purchase Threshold Price”). As used herein, the term “Accelerated Purchase Price”
shall mean the lesser of (i) the lowest Sale Price of the Common Stock on the Purchase Date or (ii) the lowest Purchase Price during the previous ten (10) Business Days prior to the date that the valid Accelerated Purchase Notice was
received by the Investor. However, if on any Purchase Date the Closing Sale Price of the Common Stock is below the Accelerated Purchase Threshold Price, such Accelerated Purchase shall be void and the Investor’s obligations to buy Purchase
Shares in respect of that Accelerated Purchase Notice shall be terminated. Thereafter, the Company shall again have the right to submit an Accelerated Purchase Notice as set forth herein by delivery of a new Accelerated Purchase Notice only if the
Closing Sale Price of the Common Stock is at or above the Accelerated Purchase Threshold Price on the date of the delivery of the Accelerated Purchase Notice. The Company may deliver multiple Accelerated Purchase Notices to the Investor so long as
at least two (2) Business Days have passed since the most recent Accelerated Purchase was completed. 
 (c) Payment for
Purchase Shares. The Investor shall pay to the Company an amount equal to the Purchase Amount with respect to such Purchase Shares as full payment for such Purchase Shares via wire transfer of immediately available funds on the same Business Day
that the Investor receives such Purchase Shares if they are received by the Investor before 1:00 p.m. eastern time or if received by the Investor after 1:00 p.m. eastern time, the next Business Day. The Company shall not issue any fraction of a
share of Common Stock upon any purchase. If the issuance would result in the issuance of a fraction of a share of Common Stock, the Company shall round such fraction of a share of Common Stock up or down to the nearest whole share. All payments made
under this Agreement shall be made in lawful money of the United States of America or wire transfer of immediately available funds to such account as the Company may from time to time designate by written notice in accordance with the provisions of
this Agreement. Whenever any amount expressed to be due by the terms of this Agreement is due on any day that is not a Business Day, the same shall instead be due on the next succeeding day that is a Business Day. 

(d) Compliance with Rules of Principal Market. 

(i) Exchange Cap. Subject to Section 2(d)(ii) below, the Company shall not issue or sell any Purchase
Shares or Commitment Shares pursuant to this Agreement, and the Investor shall not purchase or acquire any Purchase Shares or Commitment Shares pursuant to this Agreement, to the extent that after giving effect thereto, the aggregate number of
Purchase Shares and Commitment Shares issued pursuant to this Agreement, together with all Expense Shares issued prior to the date of this Agreement, would exceed 17,779,127 shares of Common Stock (19.99% of the 88,940,105 outstanding shares of
Common Stock on the date of this Agreement) (the “Exchange Cap”), unless and until the Company elects to solicit shareholder approval of the transactions contemplated by this Agreement and the shareholders of the Company have in
fact approved the transactions contemplated by this Agreement in accordance with the applicable rules and regulations of the Principal Market, the NASDAQ Stock Market, and the Certificate of Incorporation and By-laws of the Company. For the
avoidance of doubt, the Company may, but shall be under no obligation to, request its shareholders to approve the transactions contemplated by this Agreement; provided, that if shareholder approval is not obtained in accordance with this
Section 2(d)(i), the Exchange Cap shall be applicable for all purposes of this Agreement and the 

  
 -4-









 
transactions contemplated hereby at all times during the term of this Agreement (except as set forth in Section 2(d)(ii) below). 

(ii) At-Market Transaction. Notwithstanding Section 2(d)(i) above, the Exchange Cap shall not be
applicable for any purposes of this Agreement and the transactions contemplated hereby, solely to the extent that (and only for so long as) the Average Price shall equal or exceed the Base Price (it being hereby acknowledged and agreed that the
Exchange Cap shall be applicable for all purposes of this Agreement and the transactions contemplated hereby at all other times during the term of this Agreement, unless the shareholder approval referred to in Section 2(d)(i) is
obtained). “Average Price” means a price per Purchase Share (rounded to the nearest tenth of a cent) equal to the quotient obtained by dividing (i) the aggregate gross Purchase Price paid by the Investor for all Purchase Shares
purchased pursuant to this Agreement, by (ii) the aggregate number of Purchase Shares issued pursuant to this Agreement. “Base Price” means a price per Purchase Share equal to the sum of (i) the Signing Price and
(ii) $0.056, (subject to adjustment for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction that occurs on or after the date of this Agreement). The Company hereby represents
and warrants to the Investor that the Signing Price is greater than the consolidated closing bid price of the Common Stock as reported on the NASDAQ Stock Market immediately preceding the execution of this Agreement. 

(iii) General. The Company shall not issue any Purchase Shares or Commitment Shares pursuant to this Agreement if
such issuance (taking into account the issuance of all Expense Shares prior to the date of this Agreement) would reasonably be expected to result in a breach of the Company’s obligations under the rules and regulations of the Principal Market.
The provisions of this Section 2(c) shall be implemented in a manner otherwise than in strict conformity with the terms hereof only if necessary to ensure compliance with the rules and regulations of the Principal Market. 

(e) Beneficial Ownership Limitation. Notwithstanding anything to the contrary contained in this Agreement, the Company shall
not issue or sell, and the Investor shall not purchase or acquire, any shares of Common Stock under this Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by the Investor and its affiliates
(as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in the beneficial ownership by the Investor and its affiliates of more than 9.99% of the then issued and
outstanding shares of Common Stock (the “Beneficial Ownership Limitation”). Upon the written or oral request of the Investor, the Company shall confirm orally or in writing to the Investor within two (2) Business Days of such
request the number of shares of Common Stock then outstanding. The Investor and the Company shall each cooperate in good faith in the determinations required hereby and the application hereof. 

(f) Purchase Price Floor. The Company and the Investor shall not effect any sales and purchases under this Agreement on any
Purchase Date where the Purchase Price for any purchases of Purchase Shares would be less than the Floor Price. “Floor Price” means $.10, which shall be appropriately adjusted for any reorganization, recapitalization, non-cash
dividend, stock split or other similar transaction. 
  

	 	3.	INVESTOR’S REPRESENTATIONS AND WARRANTIES. 

 The Investor represents and warrants to the Company that as of the date hereof and as of the Commencement Date: 
 (a) Investment Purpose. The Investor is acquiring the Expense Shares, the Commitment Shares and the Purchase Shares (collectively, the “Securities”) as principal for its own
account, for 

  
 -5-









 
investment purposes, and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no
present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the
distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting the Investor’s right to sell the Securities at any time pursuant to the registration
statement described herein or otherwise in compliance with applicable federal and state securities laws and with respect to the Commitment Shares, subject to Section 5(e) hereof). The Investor is acquiring the Securities hereunder
in the ordinary course of its business. 
 (b) Accredited Investor Status. The Investor is an “accredited
investor” as that term is defined in Rule 501(a)(3) of Regulation D. 
 (c) Reliance on Exemptions. The Investor
understands that the Securities may be offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and
accuracy of, and the Investor’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Investor set forth herein in order to determine the availability of such exemptions and the eligibility of
the Investor to acquire the Securities. 
 (d) Information. The Investor has been furnished with all materials relating
to the business, finances and operations of the Company and materials relating to the offer and sales of the Securities that have been reasonably requested by the Investor, including, without limitation, the SEC Documents (as hereinafter defined).
The Investor understands that its investment in the Securities involves a high degree of risk. The Investor (i) is able to bear the economic risk of an investment in the Securities including a total loss of its investment with respect to the
Securities, (ii) has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the proposed investment in the Securities and (iii) has had an opportunity to ask questions of
and receive answers from the officers of the Company concerning the financial condition and business of the Company and others matters related to an investment in the Securities. Neither such inquiries nor any other due diligence investigations
conducted by the Investor or its representatives shall modify, amend or affect the Investor’s right to rely on the Company’s representations and warranties contained in Section 4 below. The Investor has sought such accounting, legal
and tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition of the Securities and is not relying on the Company or its advisors with respect thereto. 

(e) No Governmental Review. The Investor understands that no United States federal or state agency or any other government or
governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the
Securities. 
 (f) Transfer or Sale. The Investor understands that except as provided in the Registration Rights
Agreement (as hereinafter defined) (i) the Securities have not been and are not being registered under the Securities Act or any state securities laws, (ii)the Securities may not be offered for sale, sold, assigned or transferred unless
(A) registered pursuant to the Securities Act or (B) an exemption exists permitting such Securities to be sold, assigned or transferred without such registration; (iii) any sale of the Securities made in reliance on Rule 144 may be
made only in accordance with the terms of Rule 144 and further, if Rule 144 is not applicable, any resale of the Securities under circumstances in which the Investor (or the person through whom the sale is made) may be deemed to be an underwriter
(as that term is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules and regulations of the SEC thereunder. 

  
 -6-









 (g) Validity; Enforcement. Each of this Agreement, the Registration Rights Agreement
and each other Transaction Document (as hereinafter defined) to which the Investor is a party has been duly and validly authorized, executed and delivered on behalf of the Investor and is a valid and binding agreement of the Investor enforceable
against the Investor in accordance with its terms, subject as to enforceability to general principles of equity and to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting
generally, the enforcement of applicable creditors’ rights and remedies. 
 (h) Residency. The Investor is a
resident of the State of Illinois. 
 (i) No Prior Short Selling. The Investor represents and warrants to the Company
that at no time prior to the date of this Agreement has any of the Investor, its agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any (i) “short sale” (as such term is
defined in Section 242.200 of Regulation SHO of the Exchange Act) of the Common Stock or (ii) hedging transaction, which establishes a net short position with respect to the Common Stock. 

 

	 	4.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY. 

 The Company represents and warrants to the Investor that as of the date hereof and as of the Commencement Date: 
 (a) Organization and Qualification. The Company and each of the Subsidiaries (which for purposes of this Agreement means any entity in which the Company, directly or indirectly, owns 50% or more of
the voting stock or capital stock or other similar equity interests) is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the
requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation or default of any of the provisions of its respective certificate
or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each
jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to
result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or
otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i),
(ii) or (iii), a “Material Adverse Effect”) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. The
Company has no Subsidiaries except as set forth on Schedule 4(a). 
 (b) Authorization; Enforcement; Validity.
(i) The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement, the Registration Rights Agreement and each of the other agreements entered into by the parties on the Commencement
Date and attached hereto as exhibits to this Agreement (collectively, the “Transaction Documents”), and to issue the Securities in accordance with the terms hereof and thereof, (ii) the execution and delivery of the Transaction
Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby, including without limitation, the issuance of the Commitment Shares and the reservation for issuance and the issuance of the Purchase Shares (up
to the Exchange Cap) issuable under this Agreement, have been duly authorized by the Company’s Board of Directors and no further consent 

  
 -7-









 
or authorization is required by the Company, its Board of Directors or its shareholders, (iii) this Agreement has been, and each other Transaction Document shall be on the Commencement Date,
duly executed and delivered by the Company and (iv) this Agreement constitutes, and each other Transaction Document upon its execution on behalf of the Company, shall constitute, the valid and binding obligations of the Company enforceable
against the Company in accordance with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting
generally, the enforcement of creditors’ rights and remedies. The Board of Directors of the Company has approved the resolutions (the “Signing Resolutions”) substantially in the form as set forth as Exhibit C attached
hereto to authorize this Agreement and the transactions contemplated hereby. The Signing Resolutions are valid, in full force and effect and have not been modified or supplemented in any respect. No other approvals or consents of the Company’s
Board of Directors and/or shareholders is necessary under applicable laws and the Company’s Certificate of Incorporation and/or Bylaws to authorize the execution and delivery of this Agreement or any of the transactions contemplated hereby,
including, but not limited to, the issuance of the Commitment Shares and the issuance of the Purchase Shares up to the Exchange Cap. 
 (c) Capitalization. As of the date hereof, the authorized capital stock of the Company is set forth on Schedule 4(c). Except as disclosed in Schedule 4(c), (i) no shares of the
Company’s capital stock are subject to preemptive rights or any other similar rights or any liens or encumbrances suffered or permitted by the Company, (ii) there are no outstanding debt securities, (iii) there are no outstanding
options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries, or contracts,
commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe
to, calls or commitments of any character whatsoever relating to, or securities or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries, (iv) there are no agreements or arrangements under which the
Company or any of its Subsidiaries is obligated to register the sale of any of their securities under the Securities Act (except the Registration Rights Agreement), (v) there are no outstanding securities or instruments of the Company or any of
its Subsidiaries which contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any of its Subsidiaries is or may become bound to redeem a security of the Company
or any of its Subsidiaries, (vi) there are no securities or instruments containing anti-dilution or similar provisions that will be triggered by the issuance of the Securities as described in this Agreement and (vii) the Company does not
have any stock appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement. The Company has furnished to the Investor true and correct copies of the Company’s Certificate of Incorporation, as amended
and as in effect on the date hereof (the “Certificate of Incorporation”), and the Company’s By-laws, as amended and as in effect on the date hereof (the “By-laws”). 

(d) Issuance of Securities. Upon issuance and payment therefor in accordance with the terms and conditions of this Agreement, the
Purchase Shares shall be validly issued, fully paid and nonassessable and free from all taxes, liens and charges with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock. The Commitment
Shares have been duly authorized and, upon issuance in accordance with the terms hereof, the Commitment Shares shall be (i) validly issued, fully paid and non-assessable and (ii) free from all taxes, liens and charges with respect to the
issue thereof. 17,779,000 shares of Common Stock have been duly authorized and reserved for issuance upon purchase under this Agreement as Purchase Shares. 1,221,000 shares of Common Stock (subject to equitable adjustment for any reorganization,
recapitalization, non-cash dividend, stock split or other similar transaction) have been duly authorized and reserved for issuance as Additional Commitment Shares in accordance with this Agreement. The Expense Shares have been duly authorized and
are validly 

  
 -8-









 
issued, fully paid and non-assessable and free from all taxes, liens and charges with respect to the issue thereof. 
 (e) No Conflicts. Except as disclosed in Schedule 4(e), the execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company of the
transactions contemplated hereby and thereby (subject to the Exchange Cap, to the extent applicable, including, without limitation, the reservation for issuance and issuance of the Purchase Shares and Additional Commitment Shares) will not
(i) result in a violation of the Certificate of Incorporation, any Certificate of Designations, Preferences and Rights of any outstanding series of preferred stock of the Company or the By-laws or (ii) conflict with, or constitute a
default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or
any of its Subsidiaries is a party, or result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and the rules and regulations of the Principal Market applicable to the
Company or any of its Subsidiaries) or by which any property or asset of the Company or any of its Subsidiaries is bound or affected, except in the case of conflicts, defaults, terminations, amendments, accelerations, cancellations and violations
under clause (ii), which could not reasonably be expected to result in a Material Adverse Effect. Except as disclosed in Schedule 4(e), neither the Company nor its Subsidiaries is in violation of any term of or in default under its
Certificate of Incorporation, any Certificate of Designation, Preferences and Rights of any outstanding series of preferred stock of the Company or By-laws or their organizational charter or by-laws, respectively. Except as disclosed in Schedule
4(e), neither the Company nor any of its Subsidiaries is in violation of any term of or is in default under any material contract, agreement, mortgage, indebtedness, indenture, instrument, judgment, decree or order or any statute, rule or
regulation applicable to the Company or its Subsidiaries, except for possible conflicts, defaults, terminations or amendments which could not reasonably be expected to have a Material Adverse Effect. The business of the Company and its Subsidiaries
is not being conducted, and shall not be conducted, in violation of any law, ordinance, or regulation of any governmental entity, except for possible violations, the sanctions for which either individually or in the aggregate could not reasonably be
expected to have a Material Adverse Effect. Except as specifically contemplated by this Agreement and as required under the Securities Act or applicable state securities laws or Principal Market, the Company is not required to obtain any consent,
authorization or order of, or make any filing or registration with, any court or governmental agency or any regulatory or self-regulatory agency in order for it to execute, deliver or perform any of its obligations under or contemplated by the
Transaction Documents in accordance with the terms hereof or thereof. Except as disclosed in Schedule 4(e), all consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the preceding
sentence shall be obtained or effected on or prior to the Commencement Date. Except as disclosed in the SEC Documents, since one year prior to the date hereof, the Company has not received nor delivered any notices or correspondence from or to the
Principal Market. As of the date hereof, and except as disclosed in the SEC Documents, the Principal Market has not commenced any delisting proceedings against the Company. 
 (f) SEC Documents; Financial Statements. Except as disclosed in Schedule 4(f) the Company has filed all reports, schedules, forms, statements and other documents required to be filed by
the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such
material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “SEC Documents”) on a timely basis or has received a valid extension of
such time of filing and has filed any such SEC Documents prior to the expiration of any such extension. As of their respective dates, the SEC Documents complied in all material respects with the requirements of the Securities Act and the
Exchange Act, as applicable, and none of the SEC Documents, when filed, contained any untrue 

  
 -9-









 
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The financial statements of the Company included in the SEC Documents comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in
effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”), except as
may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the
Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.
Except as listed in Schedule 4(f), the Company has received no notices or correspondence from the SEC for the one year preceding the date hereof. The SEC has not commenced any enforcement proceedings against the Company or any of its
subsidiaries. 
 (g) Absence of Certain Changes. Except as disclosed in SEC Documents, since the filing of the
Company’s Form 10-Q for the period ended June 30, 2011, there has been no material adverse change in the business, properties, operations, financial condition or results of operations of the Company or its Subsidiaries. The Company has not
taken any steps, and does not currently expect to take any steps, to seek protection pursuant to any Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate
involuntary bankruptcy or insolvency proceedings. The Company is financially solvent and is generally able to pay its debts as they become due.  
 (h) Absence of Litigation. Except as disclosed in Schedule 4(h), there is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency,
self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries, threatened against or affecting the Company, the Common Stock or any of the Company’s Subsidiaries or any of the Company’s or the
Company’s Subsidiaries’ officers or directors in their capacities as such, which could reasonably be expected to have a Material Adverse Effect. A description of each action, suit, proceeding, inquiry or investigation before or by any
court, public board, government agency, self-regulatory organization or body which, as of the date of this Agreement, is pending or threatened in writing against or affecting the Company, the Common Stock or any of the Company’s Subsidiaries or
any of the Company’s or the Company’s Subsidiaries’ officers or directors in their capacities as such, is set forth in Schedule 4(h). 
 (i) Acknowledgment Regarding Investor’s Status. The Company acknowledges and agrees that the Investor is acting solely in the capacity of arm’s length purchaser with respect to the
Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the
Transaction Documents and the transactions contemplated hereby and thereby and any advice given by the Investor or any of its representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby and thereby
is merely incidental to the Investor’s purchase of the Securities. The Company further represents to the Investor that the Company’s decision to enter into the Transaction Documents has been based solely on the independent evaluation by
the Company and its representatives and advisors. 
 (j) No General Solicitation. Neither the Company, nor any of its
affiliates, nor any person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with the offer or sale of the Securities.


  
 -10-









 (k) Intellectual Property Rights. The Company and its Subsidiaries own or possess
adequate rights or licenses to use all material trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals, governmental authorizations, trade secrets and
rights necessary to conduct their respective businesses as now conducted. Except as set forth on Schedule 4(k), none of the Company’s material trademarks, trade names, service marks, service mark registrations, service names, patents,
patent rights, copyrights, inventions, licenses, approvals, government authorizations, trade secrets or other intellectual property rights have expired or terminated. The Company and its Subsidiaries do not have any knowledge of any infringement by
the Company or its Subsidiaries of any material trademark, trade name rights, patents, patent rights, copyrights, inventions, licenses, service names, service marks, service mark registrations, trade secret or other similar rights of any third
Person and, except as set forth on Schedule 4(k), there is no claim, action or proceeding pending against, or to the Company’s knowledge, being threatened against, the Company or its Subsidiaries regarding trademark, trade name, patents,
patent rights, invention, copyright, license, service names, service marks, service mark registrations, trade secret or other infringement, which could reasonably be expected to have a Material Adverse Effect. 

(l) Environmental Laws. The Company and its Subsidiaries (i) are in compliance with any and all applicable foreign, federal,
state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received all
permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where, in
each of the three foregoing clauses, the failure to so comply could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 
 (m) Title. Neither the Company nor any of its Subsidiaries owns any real properly. The Company and its Subsidiaries have good and marketable title in all personal property owned by them that is
material to the business of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects (“Liens”), except for Liens as do not materially affect the value of such property and do not
materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries, and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to
penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance with such exceptions
as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its Subsidiaries. 
 (n) Insurance. The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as management of the Company
believes to be prudent and customary in the businesses in which the Company and its Subsidiaries are engaged. Neither the Company nor any such Subsidiary has been refused any insurance coverage sought or applied for and neither the Company nor any
such Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost
that would not materially and adversely affect the condition, financial or otherwise, or the earnings, business or operations of the Company and its Subsidiaries, taken as a whole. 

(o) Regulatory Permits. The Company and its Subsidiaries possess all material certificates, authorizations and permits issued by
the appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses, and neither the Company nor any such Subsidiary has 

  
 -11-









 
received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit. 

(p) Tax Status. The Company and each of its Subsidiaries has made or filed all federal and state income and all other material tax
returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the Company and each of its Subsidiaries has set aside on its books provisions reasonably adequate for the payment of all
unpaid and unreported taxes) and has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except those being contested in good faith and
has set aside on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by
the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim. 
 (q)
Transactions With Affiliates. Except as set forth in the SEC Documents, none of the officers or directors of the Company and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with
the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property
to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director,
trustee or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits,
including stock option agreements under any stock option plan of the Company. 
 (r) Application of Takeover Protections.
The Company and its board of directors have taken or will take prior to the Commencement Date all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or other similar anti-takeover provision under the Certificate of Incorporation or the laws of the state of its incorporation which is or could become applicable to the Investor as a result of the transactions contemplated
by this Agreement, including, without limitation, the Company’s issuance of the Securities and the Commitment Shares and the Investor’s ownership of the Securities and the Commitment Shares. 

(s) Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided the Investor or its agents or counsel with any information that it believes constitutes or might constitute material, non-public information which
is not otherwise disclosed in the Registration Statement or prospectus supplements thereto or otherwise made publicly available. The Company understands and confirms that the Investor will rely on the foregoing representation in effecting
purchases and sales of securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Investor regarding the Company, its business and the transactions contemplated hereby, including the disclosure schedules to
this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not
misleading. The Company acknowledges and agrees that the Investor neither makes nor has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3
hereof. 

  
 -12-









 (t) Foreign Corrupt Practices. Neither the Company, nor to the knowledge of the
Company, any agent or other person acting on behalf of the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity,
(ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company
(or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended. 

 

	 	5.	COVENANTS. 

 (a) Filing
of Form 8-K and Registration Statement. The Company agrees that it shall, within the time required under the Exchange Act file a Report on Form 8-K disclosing this Agreement and the transaction contemplated hereby. The Company shall also file
within twenty (20) Business Days from the date hereof a new registration statement (“Registration Statement”) covering only the resale of the Purchase Shares, the Commitment Shares and the Expense Shares, in accordance with the
terms of the Registration Rights Agreement between the Company and the Investor, dated as of the date hereof (“Registration Rights Agreement”). Any securities issuable under this Agreement that have not been registered under the
Securities Act shall bear the following restrictive legend (the “Restrictive Legend”): 
 THE SECURITIES
REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR
ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, UNLESS SOLD PURSUANT TO: (1) RULE 144 UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR (2) AN OPINION OF HOLDER’S COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS. 
 (b) Blue Sky. The Company has taken all such action, if any, as is reasonably necessary in order to obtain an exemption for or to qualify (i) the initial issuance of the Expense Shares and
Initial Commitment Shares to the Investor under this Agreement and (ii) any subsequent resale of the Expense Shares and the Initial Commitment Shares by the Investor, in each case, under applicable securities or “Blue Sky” laws of the
states of the United States in such states as reasonably requested by the Investor, and will provide evidence of any such action so taken to the Investor, and the Company shall continue to use its commercially reasonable efforts to maintain in
effect such exemption or qualification, as applicable. The Company shall use its commercially reasonable efforts to take such action, if any, as is reasonably necessary in order to obtain an exemption for or to qualify (x) the initial issuance
or sale of any Additional Commitment Shares and any Purchase Shares to the Investor under this Agreement and (y) any subsequent resale of any Additional Commitment Shares and any Purchase Shares by the Investor, in each case, under applicable
securities or “Blue Sky” laws of the states of the United States in such states as is reasonably requested by the Investor from time to time, and shall provide evidence of any such action so taken to the Investor, and the Company shall
continue to use its commercially reasonable efforts to maintain in effect such exemption or qualification, as applicable; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (x) qualify
to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 5(b), (y) subject itself 

  
 -13-









 
to general taxation in any such jurisdiction or (z) file a general consent to service of process in any such jurisdiction. 

(c) Listing. The Company shall promptly secure the listing of all of the Purchase Shares, Commitment Shares and Expense Shares
upon such Principal Market (subject to official notice of issuance) and shall maintain, so long as any other shares of Common Stock shall be so listed, such listing of all such securities from time to time issuable under the terms of the Transaction
Documents. The Company shall maintain the Common Stock’s authorization for quotation on the Principal Market. The Company shall promptly, and in no event later than the following Business Day, provide to the Investor copies of any notices it
receives from the Principal Market regarding the continued eligibility of the Common Stock for listing on such Principal Market. The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section 5(c).

 (d) Limitation on Short Sales and Hedging Transactions. The Investor agrees that beginning on the date of this
Agreement and ending on the date of termination of this Agreement as provided in Section 11, the Investor and its agents, representatives and affiliates shall not in any manner whatsoever enter into or effect, directly or indirectly, any
(i) “short sale” (as such term is defined in Section 242.200 of Regulation SHO of the Exchange Act) of the Common Stock or (ii) hedging transaction, which establishes a net short position with respect to the Common Stock.

 (e) Issuance of Commitment Shares. Immediately upon the execution of this Agreement, the Company shall issue to the
Investor (to an account designated by the Investor no later than one (1) Business Day prior to the date hereof) as consideration for the Investor entering into this Agreement 1,452,785 shares of Common Stock (the “Initial Commitment
Shares”) and shall deliver to the Transfer Agent a letter in the form as set forth as Exhibit E attached hereto with respect to the issuance of the Initial Commitment Shares. In connection with each purchase of Purchase Shares
hereunder, the Company agrees to issue to the Investor a number of shares of Common Stock (the “Additional Commitment Shares” and together with the Initial Commitment Shares, the “Commitment Shares”) equal to the
product of (x) 2,905,569 and (y) the Purchase Amount Fraction. The “Purchase Amount Fraction” shall mean a fraction, the numerator of which is the Purchase Amount purchased by the Investor with respect to such purchase of
Purchase Shares and the denominator of which is Fifteen Million Dollars ($15,000,000). The Additional Commitment Shares shall be equitably adjusted for any reorganization, recapitalization, non-cash dividend, stock split or other similar
transaction. The Initial Commitment Shares shall be issued in certificated form and shall bear the Restrictive Legend. 
 (f)
Due Diligence. The Investor shall have the right, from time to time as the Investor may reasonably deem appropriate, to perform reasonable due diligence on the Company during normal business hours. The Company and its officers and employees
shall provide information and reasonably cooperate with the Investor in connection with any reasonable request by the Investor related to the Investor’s due diligence of the Company. Each party hereto agrees not to disclose any Confidential
Information of the other party to any third party and shall not use the Confidential Information for any purpose other than in connection with, or in furtherance of, the transactions contemplated hereby. Each party hereto acknowledges that the
Confidential Information shall remain the property of the disclosing party and agrees that it shall take all reasonable measures to protect the secrecy of any Confidential Information disclosed by the other party. The Company confirms that neither
it nor any other Person acting on its behalf shall provide the Investor or its agents or counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in any SEC
Document the Registration Statement or prospectus supplements thereto or otherwise publicly disclosed. 

  
 -14-









 (g) Purchase Records. The Investor and the Company shall each maintain records
showing the remaining Available Amount at any given time and the dates and Purchase Amounts for each purchase or shall use such other method, reasonably satisfactory to the Investor and the Company. 

(h) Taxes. The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the issuance and
delivery of any shares of Common Stock to the Investor made under this Agreement. 
 (i) Limitation of Variable Rate
Transactions. This Agreement does not limit in any way the Company’s right to enter into and perform any Variable Rate Transaction, except that from the date hereof until the earlier of (a) the date that is twelve (12) months
following the termination of this Agreement by the Company pursuant to Section 11(d) (the “Tail Period”) and (b) the Maturity Date, the Company will not enter into any transaction that has a substantially similar structure to the
transaction contemplated by this Agreement (a “Similar Transaction”) other than with the Investor; provided, further, that the Company shall have the right to enter into and perform a Similar Transaction (A) during the Tail Period, if
at any time during the term of this Agreement the Company was prohibited from issuing any Purchase Shares to the Investor as a result of the limitations set forth in to Section 2(c)(i) and/or Section 2(d), or (B) after the Maturity
Date. 
 “Variable Rate Transaction” means a transaction in which the Company (i) issues or sells any debt
or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based
upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being
reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock (excluding
customary anti-dilution provisions) including without limitation, such anti-dilution provisions whereby the exercise price of a convertible security, or the number of shares issuable upon exercise thereof, may be adjusted based on subsequent
financing transactions) or (ii) enters into any agreement, including, but not limited to, an equity line of credit or at the market offering, whereby the Company may sell securities at a future determined price. 

(j) Notice of Transactions. For eighteen (18) Monthly Periods from the date hereof, the Company agrees that prior to entering
into each and any definitive agreement for the sale directly or indirectly of any debt, Common Stock or Common Stock Equivalents, primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, to
which definitive agreement, or series of related definitive agreements taken together, there are two (2) or more counterparties (not including the Company) (a “Subsequent Transaction”), the Company shall provide reasonable,
good faith notice to the Investor (“Offering Notice”) consistent with the notice given to all other potential investors in such Subsequent Transaction, including the relevant terms and conditions of such Subsequent Transaction as
are delivered to all other potential investors, and the Investor shall have the right to participate on equivalent terms and conditions in up to 10% of such Subsequent Transaction by delivering notice to the Company by such deadline (the
“Participation Deadline”) as shall be determined by the underwriter or the investment banker involved in the transaction, or in the absence of either an underwriter or an investment banker, the Company, and applicable to all
potential investors in such Subsequent Transaction, which notice from Investor shall indicate Investor’s intention to participate in the Subsequent Transaction and the amount of its participation. In the event that the Investor does not provide
notice prior to the Participation Deadline and the Company does not enter into such Subsequent Transaction within five (5) Business Days from the Offering Notice, the Company shall again be required to provide an Offering Notice as set forth
herein. The Company shall deliver an Offering Notice for each 

  
 -15-









 
and any Subsequent Transaction and agrees that it shall not execute any definitive documentation for any Subsequent Transaction whatsoever, unless it has first complied with this
Section 5(j). Notwithstanding anything to the contrary in this Section 5(j) and unless otherwise agreed to by Investor, the Company shall either confirm in writing to Investor that the transaction with respect to the Subsequent Transaction
has been abandoned or shall publicly disclose its intention to enter into the Subsequent Transaction, in either case in such a manner such that Investor will not be in possession of any material, non-public information, by the fifth (5th) Business Day following delivery of the Offering Notice. If by
such fifth (5th) Business Day, no public disclosure
regarding a transaction with respect to the Subsequent Transaction has been made, and no notice regarding the abandonment of such transaction has been received by Investor, such transaction shall be deemed to have been abandoned and Investor shall
not be in possession of any material, non-public information with respect to the Company or any of its Subsidiaries. Should the Company decide to pursue such transaction with respect to the Subsequent Transaction, the Company shall provide Investor
with another Offering Notice in accordance with, and subject to, the terms of this Section 5(j) and Investor will again have the right of participation set forth in this Section 5(j). 

 

	 	6.	TRANSFER AGENT INSTRUCTIONS. 

 On the Commencement Date, the Company shall cause any restrictive legend on the Expense Shares and the Initial Commitment Shares to be removed and all of the Purchase Shares and Additional Commitment
Shares, to be issued under this Agreement shall be issued without any restrictive legend unless the Investor expressly consents otherwise. The Company shall issue irrevocable instructions to the Transfer Agent, and any subsequent transfer agent, to
issue Additional Commitment Shares and Purchase Shares in the name of the Investor in the form agreed to by the parties prior to the Commencement Date (the “Irrevocable Transfer Agent Instructions”). The Company warrants to the
Investor that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 6, will be given by the Company to the Transfer Agent with respect to the Purchase Shares and the Additional Commitment Shares, and
that the Expense Shares, the Commitment Shares and the Purchase Shares shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement. 

 

	 	7.	CONDITIONS TO THE COMPANY’S RIGHT TO COMMENCE SALES OF SHARES OF COMMON STOCK. 


The right of the Company hereunder to commence sales of the Purchase Shares is subject to the satisfaction of each of the following
conditions: 
 (a) The Investor shall have executed each of the Transaction Documents and delivered the same to the Company; and

 (b) A registration statement covering the sale of all of the Expense Shares, Commitment Shares and Purchase Shares shall have
been declared effective under the Securities Act by the SEC and no stop order with respect to the registration statement shall be pending or threatened by the SEC. 
 (c) The representations and warranties of the Investor shall be true and correct in all material respects (except to the extent that any of such representations and warranties is already qualified as to
materiality, in which case such representations and warranties shall be true and correct without further qualification) as of the date when made and as of the Commencement Date as though made at that time (except for representations and warranties
that speak as of a specific date) and the Investor shall have performed, satisfied and complied with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Investor at or
prior to the Commencement Date. 

  
 -16-










	 	8.	CONDITIONS TO THE INVESTOR’S OBLIGATION TO PURCHASE SHARES OF COMMON STOCK. 


The obligation of the Investor to buy Purchase Shares under this Agreement is subject to the satisfaction of each of the following
conditions and once such conditions have been initially satisfied, there shall not be any ongoing obligation to satisfy such conditions after the Commencement has occurred: 
 (a) The Company shall have executed each of the Transaction Documents and delivered the same to the Investor; 
 (b) The Company shall have issued to the Investor the Expense Shares and the Initial Commitment Shares without restrictive legend; 
 (c) The Common Stock shall be authorized for quotation on the Principal Market, trading in the Common Stock shall not have been within the last 365 days suspended by the SEC or the Principal Market and
the Expense Shares, the Purchase Shares and the Commitment Shares shall be approved for listing upon the Principal Market; 

(d) The Investor shall have received the opinions of the Company’s legal counsel dated as of the Commencement Date substantially in
the form of Exhibit A attached hereto; 
 (e) The representations and warranties of the Company shall be true and
correct in all material respects (except to the extent that any of such representations and warranties is already qualified as to materiality in Section 4 above, in which case, such representations and warranties shall be true and correct
without further qualification) as of the date when made and as of the Commencement Date as though made at that time (except for representations and warranties that speak as of a specific date) and the Company shall have performed, satisfied and
complied with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the Commencement Date. The Investor shall have received a certificate, executed by
the CEO, President or CFO of the Company, dated as of the Commencement Date, to the foregoing effect in the form attached hereto as Exhibit B; 
 (f) The Board of Directors of the Company shall have adopted resolutions substantially in the form attached hereto as Exhibit C which shall be in full force and effect without any amendment
or supplement thereto as of the Commencement Date; 
 (g) As of the Commencement Date, the Company shall have reserved out of
its authorized and unissued Common Stock, (A) solely for the purpose of effecting purchases of Purchase Shares hereunder, 17,779,000 shares of Common Stock and (B) as Additional Commitment Shares in accordance with Section 5(e)
hereof, 1,221,000 shares of Common Stock; 
 (h) The Irrevocable Transfer Agent Instructions, in form acceptable to the parties
shall have been delivered to and acknowledged in writing by the Company and the Company’s Transfer Agent; 
 (i) The
Company shall have delivered to the Investor a certificate evidencing the incorporation and good standing of the Company in the State of Delaware issued by the Secretary of State of the State of Delaware as of a date within ten (10) Business
Days of the Commencement Date; 

  
 -17-









 (j) The Company shall have delivered to the Investor a certified copy of the Certificate of
Incorporation as certified by the Secretary of State of the State of Delaware within ten (10) Business Days of the Commencement Date; 
 (k) The Company shall have delivered to the Investor a secretary’s certificate executed by the Secretary of the Company, dated as of the Commencement Date, in the form attached hereto as
Exhibit D; 
 (l) A registration statement covering the sale of all of the Purchase Shares, the Commitment Shares
and the Expense Shares shall have been declared effective under the Securities Act by the SEC and no stop order with respect to the registration statement shall be pending or threatened by the SEC. The Company shall have prepared and delivered to
the Investor a final and complete form of prospectus, dated and current as of the Commencement Date, to be used by the Investor in connection with any sales of the Expense Shares, the Commitment Shares and any Purchase Shares, and to be filed by the
Company one (1) Business Day after the Commencement Date. The Company shall have made all filings under all applicable federal and state securities or “Blue Sky” laws necessary to consummate the issuance of the Expense Shares, the
Commitment Shares and the Purchase Shares pursuant to this Agreement in compliance with such laws; 
 (m) No Event of Default
has occurred, or any event which, after notice and/or lapse of time, would become an Event of Default has occurred; 
 (n) On or
prior to the Commencement Date, the Company shall take all necessary action, if any, and such actions as reasonably requested by the Investor, in order to render inapplicable any control share acquisition, business combination, shareholder rights
plan or poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Certificate of Incorporation or the laws of the state of its incorporation which is or could become applicable to the
Investor as a result of the transactions contemplated by this Agreement, including, without limitation, the Company’s issuance of the Expense Shares, the Commitment Shares and the Purchase Shares and the Investor’s ownership of such
securities; and 
 (o) The Company shall have provided the Investor with the information requested by the Investor in connection
with its due diligence requests made prior to, or in connection with, the Commencement, in accordance with the terms of Section 5(f) hereof. 
  

	 	9.	INDEMNIFICATION. 

 In
consideration of the Investor’s execution and delivery of the Transaction Documents and acquiring the Securities hereunder and in addition to all of the Company’s other obligations under the Transaction Documents, the Company shall defend,
protect, indemnify and hold harmless the Investor and all of its affiliates, shareholders, officers, directors, employees and direct or indirect investors and any of the foregoing person’s agents or other representatives (including, without
limitation, those retained in connection with the transactions contemplated by this Agreement) (collectively, the “Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses, costs, penalties, fees,
liabilities and damages, and expenses in connection therewith (irrespective of whether any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements (the
“Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising out of, or relating to (a) any misrepresentation or breach of any representation or warranty made by the Company in the Transaction Documents or
any other certificate, instrument or document contemplated hereby or thereby, (b) any breach of any covenant, agreement or obligation of the Company contained in the Transaction Documents or any other certificate, instrument or document
contemplated hereby or thereby, 

  
 -18-









 
or (c) any cause of action, suit or claim brought or made against such Indemnitee and arising out of or resulting from the execution, delivery, performance or enforcement of the Transaction
Documents or any other certificate, instrument or document contemplated hereby or thereby, other than with respect to Indemnified Liabilities which result from the gross negligence or willful misconduct of the Indemnitee. To the extent that the
foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities which is permissible under applicable law. 

 

	 	10.	EVENTS OF DEFAULT. 

 An
“Event of Default” shall be deemed to have occurred at any time as any of the following events occurs: 
 (a)
while any registration statement is required to be maintained effective pursuant to terms of the Registration Rights Agreement, the effectiveness of a registration statement registering any of the Expense Shares, the Commitment Shares or the
Purchase Shares lapses for any reason (including, without limitation, the issuance of a stop order) or is unavailable to the Investor for the resale of any or all of the Expense Shares, the Commitment Shares or the Purchase Shares, and such lapse or
unavailability continues for a period of ten (10) consecutive Business Days or for more than an aggregate of thirty (30) Business Days in any 365-day period; 
 (b) the suspension from trading or failure of the Common Stock to be listed on the Principal Market for a period of three (3) consecutive Business Days; 

(c) the delisting of the Company’s Common Stock from the Principal Market, provided, however, that the Common Stock is not
immediately thereafter trading on the New York Stock Exchange, the NASDAQ Capital Market, the NASDAQ Global Select Market, the OTC Bulletin Board (or nationally recognized successor thereto), or the NYSE Amex; 

(d) the failure for any reason by the Transfer Agent to issue Purchase Shares or Additional Commitment Shares to the Investor within five
(5) Business Days after the applicable Purchase Date which the Investor is entitled to receive; 
 (e) the Company breaches
any representation, warranty, covenant or other term or condition under any Transaction Document if such breach could have a Material Adverse Effect and except, in the case of a breach of a covenant which is reasonably curable, only if such breach
continues for a period of at least five (5) Business Days; 
 (f) if any Person commences a proceeding against the Company
pursuant to or within the meaning of any Bankruptcy Law; 
 (g) if the Company pursuant to or within the meaning of any
Bankruptcy Law; (A) commences a voluntary case, (B) consents to the entry of an order for relief against it in an involuntary case, (C) consents to the appointment of a Custodian of it or for all or substantially all of its property,
(D) makes a general assignment for the benefit of its creditors or is generally unable to pay its debts as the same become due; 
 (h) a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that (A) is for relief against the Company in an involuntary case, (B) appoints a Custodian of the
Company or for all or substantially all of its property, or (C) orders the liquidation of the Company or any Subsidiary; or 

  
 -19-









 (i) if at any time after the Commencement Date, the Exchange Cap is reached (to the extent
such Exchange Cap is applicable pursuant to Section 2(c) hereof. 
 In addition to any other rights and remedies under applicable
law and this Agreement, including the Investor termination rights under Section 11 hereof, so long as an Event of Default has occurred and is continuing, or if any event which, after notice and/or lapse of time, would become an Event of
Default, has occurred and is continuing, the Investor shall not be permitted or obligated to purchase any shares of Common Stock under this Agreement. If pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case
or any Person commences a proceeding against the Company, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors, (any of which would be an
Event of Default as described in Sections 10(f), 10(g) and 10(h) hereof) this Agreement shall automatically terminate without any liability or payment to the Company without further action or notice by any Person. No such termination of this
Agreement under Section 11(a) or 11(d) shall affect the Company’s or the Investor’s obligations under this Agreement with respect to pending purchases and the Company and the Investor shall complete their respective obligations with
respect to any pending purchases under this Agreement. 
  

	 	11.	TERMINATION 

 This
Agreement may be terminated only as follows: 
 (a) If pursuant to or within the meaning of any Bankruptcy Law, the Company
commences a voluntary case or any Person commences a proceeding against the Company, a Custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its
creditors, (any of which would be an Event of Default as described in Sections 10(f), 10(g) and 10(h) hereof) this Agreement shall automatically terminate without any liability or payment to the Company without further action or notice by any
Person. No such termination of this Agreement under this Section 11(a) shall affect the Company’s or the Investor’s obligations under this Agreement with respect to pending purchases and the Company and the Investor shall complete
their respective obligations with respect to any pending purchases under this Agreement. 
 (b) In the event that the
Commencement shall not have occurred, the Company shall have the option to terminate this Agreement for any reason or for no reason without any liability whatsoever of any party to any other party under this Agreement. 

(c) In the event that the Commencement shall not have occurred on or before December 31, 2011, due to the failure to satisfy the
conditions set forth in Sections 7 and 8 above with respect to the Commencement, the non-breaching party shall have the option to terminate this Agreement at the close of business on such date or thereafter without liability of any party to any
other party. 
 (d) At any time after the Commencement Date, the Company shall have the option to terminate this Agreement for
any reason or for no reason by delivering notice (a “Company Termination Notice”) to the Investor electing to terminate this Agreement without any liability whatsoever of any party to any other party under this Agreement. The
Company Termination Notice shall not be effective until one (1) Business Day after it has been received by the Investor. No such termination of this Agreement under this Section 11(d) shall affect the Company’s or the Investor’s
obligations under this Agreement with respect to pending purchases and the Company and the Investor shall complete their respective obligations with respect to any pending purchases under this Agreement. 

  
 -20-









 (e) This Agreement shall automatically terminate on the date that the Company sells and the
Investor purchases the full Available Amount as provided herein, without any action or notice on the part of any party and without any liability whatsoever of any party to any other party under this Agreement. 

(f) If by the Maturity Date for any reason or for no reason the full Available Amount under this Agreement has not been purchased as
provided for in Section 2 of this Agreement, this Agreement shall automatically terminate on the Maturity Date, without any action or notice on the part of any party and without any liability whatsoever of any party to any other party under
this Agreement. 
 Except as set forth in Sections 11(a) (in respect of an Event of Default under Sections 10(f), 10(g) and 10(h)), 11(c) and
11(f), any termination of this Agreement pursuant to this Section 11 shall be effected by written notice from the Company to the Investor, or the Investor to the Company, as the case may be, setting forth the basis for the termination hereof.
The representations and warranties and covenants of the Company and the Investor contained in Sections 3, 4, 5, and 6 hereof, the indemnification provisions set forth in Section 9 hereof and the agreements and covenants set forth in Sections
10, 11 and 12 shall survive the Commencement and any termination of this Agreement. No termination of this Agreement shall affect the Company’s or the Investor’s rights or obligations (i) under the Registration Rights Agreement which
shall survive any such termination or (ii) under this Agreement with respect to pending purchases and the Company and the Investor shall complete their respective obligations with respect to any pending purchases under this Agreement.

  

	 	12.	MISCELLANEOUS. 

 (a)
Governing Law; Jurisdiction; Jury Trial. The corporate laws of the State of Delaware shall govern all issues concerning the relative rights of the Company and its shareholders. All other questions concerning the construction, validity,
enforcement and interpretation of this Agreement and the other Transaction Documents shall be governed by the internal laws of the State of Illinois, without giving effect to any choice of law or conflict of law provision or rule (whether of the
State of Illinois or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Illinois. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of Chicago, for the adjudication of any dispute hereunder or under the other Transaction Documents or in connection herewith or therewith, or with any transaction contemplated hereby or discussed herein, and hereby irrevocably
waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such
suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such
notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner
permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION
CONTEMPLATED HEREBY. 
 (b) Counterparts. This Agreement may be executed in two or more identical counterparts, all
of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature or signature delivered by e-mail in a
“.pdf” format data file shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile signature or a signature in a “.pdf”
format data file. 

  
 -21-









 (c) Headings. The headings of this Agreement are for convenience of reference and
shall not form part of, or affect the interpretation of, this Agreement. 
 (d) Severability. If any provision of this
Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any
provision of this Agreement in any other jurisdiction. 
 (e) Entire Agreement. This Agreement supersedes all other prior
oral or written agreements between the Investor, the Company, their affiliates and persons acting on their behalf with respect to the matters discussed herein, and this Agreement, the other Transaction Documents and the instruments referenced herein
contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Investor makes any representation, warranty, covenant or
undertaking with respect to such matters. The Company acknowledges and agrees that is has not relied on, in any manner whatsoever, any representations or statements, written or oral, other than as expressly set forth in the Transaction Documents.

 (f) Notices. Any notices, consents or other communications required or permitted to be given under the terms of this
Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt when delivered personally; (ii) upon receipt when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated
and kept on file by the sending party); or (iii) one Business Day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to the party to receive the same. The addresses and facsimile numbers for
such communications shall be: 
 If to the Company: 
 Marina Biotech, Inc. 
 3830 Monte Villa Parkway 

Bothell, WA 98021 

			
	 Telephone:
	  	425-908-3600
	 Attention:
	  	Philip C. Ranker

 With a copy to: 
 Pryor Cashman LLP 
 7 Times Square, 40th Floor 

New York, NY 10036 

			
	 Telephone:
	  	212-326-0881
	Facsimile:	  	212-798-6365
	Attention:	  	H. Lawrence Remmel, Esq.

 If to the Investor: 
 Lincoln Park Capital Fund, LLC 
 440 North Wells, Suite 620 

Chicago, IL 60654 

			
	 Telephone:
	  	312-822-9300
	Facsimile:	  	312-822-9301
	Attention:	  	Josh Scheinfeld/Jonathan Cope


  
 -22-









 With a copy to: 
 Greenberg Traurig, LLP 
 The MetLife Building 

200 Park Avenue 

New York, NY 10166 

			
	 Telephone:
	  	212-801-9200
	Facsimile:	  	212-801-6400
	Attention:	  	Anthony J. Marsico

 If to the Transfer Agent: 
 American Stock Transfer & Trust Company, LLC 
 6201 15th Avenue

 Brooklyn, NY 11219 

			
	 Telephone:
	  	718-921-8200
	Facsimile:	  	________________
	Attention:	  	________________

 or at such other address and/or facsimile number and/or to the attention of such other person as the recipient party has
specified by written notice given to each other party three (3) Business Days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent or other communication,
(B) mechanically or electronically generated by the sender’s facsimile machine containing the time, date, and recipient facsimile number or (C) provided by a nationally recognized overnight delivery service, shall be rebuttable
evidence of personal service, receipt by facsimile or receipt from a nationally recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above, respectively. 

(g) Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective
successors and permitted assigns. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investor, including by merger or consolidation. The Investor may not assign its rights or
obligations under this Agreement. 
 (h) No Third Party Beneficiaries. This Agreement is intended for the benefit of the
parties hereto and their respective successors and permitted assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person. 
 (i) Publicity. The Investor shall have the right to approve before issuance any press release, SEC filing or any other public disclosure made by or on behalf of the Company whatsoever with respect
to, in any manner, the Investor, its purchases hereunder or any aspect of this Agreement or the transactions contemplated hereby; provided, however, that the Company shall be entitled, without the prior approval of the Investor, to make any press
release or other public disclosure (including any filings with the SEC) with respect to such transactions as is required by applicable law and regulations so long as the Company and its counsel consult with the Investor in connection with any such
press release or other public disclosure at least two (2) Business Days prior to its release. The Investor must be provided with a copy thereof at least two (2) Business Days prior to any release or use by the Company thereof. The Company
agrees and acknowledges that its failure to fully comply with this provision constitutes a material adverse effect on its ability to perform its obligations under this Agreement. 

(j) Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and
shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and 

  
 -23-









 
accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby. 
 (k) No Financial Advisor, Placement Agent, Broker or Finder. The Company represents and warrants to the Investor that it has not engaged any financial advisor, placement agent, broker or finder in
connection with the transactions contemplated hereby. The Investor represents and warrants to the Company that it has not engaged any financial advisor, placement agent, broker or finder in connection with the transactions contemplated hereby. The
Company shall be responsible for the payment of any fees or commissions, if any, of any financial advisor, placement agent, broker or finder engaged by it relating to or arising out of the transactions contemplated hereby. The Investor shall be
responsible for the payment of any fees or commissions, if any, of any financial advisor, placement agent, broker or finder engaged by it relating to or arising out of the transactions contemplated hereby. 

(l) No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party. 
 (m) Remedies, Other
Obligations, Breaches and Injunctive Relief. The Investor’s remedies provided in this Agreement shall be cumulative and in addition to all other remedies available to the Investor under this Agreement, at law or in equity (including a
decree of specific performance and/or other injunctive relief), no remedy of the Investor contained herein shall be deemed a waiver of compliance with the provisions giving rise to such remedy and nothing herein shall limit the Investor’s right
to pursue actual damages for any failure by the Company to comply with the terms of this Agreement. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Investor and that the remedy at law for
any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the Investor shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without
the necessity of showing economic loss and without any bond or other security being required. 
 (n) Enforcement Costs.
If: (i) this Agreement is placed by the Investor in the hands of an attorney for enforcement or is enforced by the Investor through any legal proceeding; or (ii) an attorney is retained to represent the Investor in any bankruptcy,
reorganization, receivership or other proceedings affecting creditors’ rights and involving a claim under this Agreement, then the Company shall pay to the Investor, as incurred by the Investor, all reasonable costs and expenses including
attorneys’ fees incurred in connection therewith, in addition to all other amounts due hereunder. 
 (o) Failure or
Indulgence Not Waiver. No failure or delay in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further
exercise thereof or of any other right, power or privilege. 
 (p) Costs and Expenses. Except for such amounts as have
been required to be paid on or prior to the date hereof, each party shall pay all costs and expenses incurred by it in connection with the preparation, negotiation, execution and delivery of this Agreement and the other Transaction Documents.

 *    *    *    *    * 

  
 -24-









 IN WITNESS WHEREOF, the Investor and the Company have caused this Purchase Agreement
to be duly executed as of the date first written above. 
  

			
	THE COMPANY:
	
	MARINA BIOTECH, INC.
		
	By:	 	/s/ Phil Ranker
	Name:	 	Phil Ranker
	Title:	 	Interim CFO
	
	INVESTOR:
	
	 LINCOLN PARK CAPITAL FUND, LLC
 BY: LINCOLN PARK CAPITAL, LLC
 BY: ROCKLEDGE CAPITAL CORPORATION

		
	By:	 	/s/ Josh Scheinfeld
	Name:	 	Josh Scheinfeld
	Title:	 	President



  
 -25-









 EXHIBIT A 

FORM OF COMPANY COUNSEL OPINION 
 Capitalized terms used herein but not defined herein, have the meaning set forth in the Purchase Agreement. Based on the foregoing, and subject to the assumptions and qualifications set forth herein, we
are of the opinion that: 
 1. The Company is a corporation existing and in good standing under the laws of the
State of Delaware. 
 2. The Company has the corporate power to execute and deliver, and perform its obligations
under, each Transaction Document to which it is a party. The Company has the corporate power to conduct its business as, to the best of our knowledge, it is now conducted, and to own and use the properties owned and used by it. 

3. The execution, delivery and performance by the Company of the Transaction Documents to which it is a party and the
consummation by it of the transactions contemplated therein have been duly authorized by all necessary corporate action on the part of the Company. The Transaction Documents to which the Company is a party have been duly executed and delivered by
the Company and are the valid and binding obligations of the Company, enforceable against the Company in accordance with their terms except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or affecting creditor’s rights and remedies or other reasonable exceptions to be set forth in such opinion. 

4. The execution, delivery and performance by the Company of the Transaction Documents, the consummation by the Company of
the transactions contemplated thereby including the offering, sale and issuance of the Expense Shares, the Commitment Shares and the Purchase Shares in accordance with the terms and conditions of the Purchase Agreement, and fulfillment and
compliance with terms of the Transaction Documents, does not and shall not: (i) conflict with, constitute a breach of or default (or an event which, with the giving of notice or lapse of time or both, constitutes or could constitute a breach or
a default), under the Certificate of Incorporation or the Bylaws of the Company, (ii) constitute a breach by the Company of, or constitute a default by the Company under, any of the agreements filed as an exhibit to the Registration Statement,
(iii) cause the Company to violate any federal, Delaware or New York law, regulation or rule (other than state securities or blue sky laws, as to which we express no opinion) known by us to be applicable to the Company, or (iv) cause the
Company to violate any decree, judgment or order of any federal, Delaware or New York state court or governmental instrumentality to which the Company or its Subsidiaries are a named party and which is known to us, except, in the case of each of
clauses (ii), (iii) and (iv) only, for those breaches, defaults and violations which would not be reasonably be expected to have a Material Adverse Effect, individually or in the aggregate. 

5. The issuance of the Purchase Shares, the Commitment Shares and the Expense Shares pursuant to the terms and conditions
of the Transaction Documents has been duly authorized and the Expense Shares and the Initial Commitment Shares are validly issued, fully paid and non-assessable, to our knowledge, free of all taxes, liens, charges, restrictions, rights of first
refusal and preemptive rights. 17,779,000 shares of Common Stock have been properly reserved for issuance under the Purchase Agreement. When issued and paid for in accordance with the Purchase Agreement, the Purchase Shares shall be validly issued,
fully paid and non-assessable, to our knowledge, free of all taxes, liens, charges, restrictions, rights of first refusal and preemptive rights. 1,221,000 shares of Common Stock have been properly reserved for issuance as Additional Commitment
Shares under the Purchase Agreement. When 







 
issued in accordance with the Purchase Agreement, the Additional Commitment Shares shall be validly issued, fully paid and non-assessable, to our knowledge, free of all taxes, liens, charges,
restrictions, rights of first refusal and preemptive rights. To our knowledge, the execution and delivery of the Registration Rights Agreement do not, and the performance by the Company of its obligations thereunder shall not, give rise to any
rights of any other person for the registration under the Securities Act of any shares of Common Stock or other securities of the Company which have not been waived. 

6. As of the date hereof, the authorized capital stock of the Company consists of 180,000,000 shares of common stock,
$.006 par value, of which to our knowledge 88,940,105 shares are issued and outstanding. Except as set forth on Schedule 4(c) of the Purchase Agreement, to our knowledge, there are no outstanding shares of capital stock or other securities
convertible into or exchangeable or exercisable for shares of the capital stock of the Company. 
 7. Assuming
the accuracy of the representations and your compliance with the covenants made by you in the Transaction Documents, the offering, sale and issuance of the Expense Shares, the Commitment Shares and the Purchase Shares to you pursuant to the
Transaction Documents is exempt from registration under the Securities Act. 
 8. No consent, approval,
authorization or order of filing with any federal or New York governmental authority or, to our knowledge, Delaware, New York or United States federal court is required for the Company’s execution and delivery of the Purchase Agreement and the
issuance of the Common Stock pursuant thereto, other than (a) those that have been made under the Securities Act, the Exchange Act or the rules of NASDAQ, (b) those under state securities or blue sky laws (as to which we express no
opinion), (c) with respect to the issuance of the Common Stock, such consents, approvals, authorizations, orders or filings as may be required after the date hereof, as and when required, under the Transaction Documents, and (d) any
necessary approval of the Financial Industry Regulatory Authority (as to which we express no opinion). 
 9. The
Common Stock is registered pursuant to Section 12(g) of the Exchange Act. To our knowledge, since one year preceding the date of the Purchase Agreement, the Company has been in compliance with the reporting requirements of the Exchange Act
applicable to it. To our knowledge, and except as stated in Schedule 4(f) of the SEC Documents, since one year preceding the date of the Purchase Agreement, the Company has not received any written notice from the Principal Market stating that the
Company has not been in compliance with any of the rules and regulations (including the requirements for continued listing) of the Principal Market. 
 We further advise you that to our knowledge, except as disclosed on Schedule 4(h) in the Purchase Agreement, there is no action, suit, proceeding, inquiry or investigation before or by any court, public
board or body, any governmental agency, any stock exchange or market, or self-regulatory organization, which has been threatened in writing or which is currently pending against the Company, any of its subsidiaries, any officers or directors of the
Company or any of its subsidiaries or any of the properties of the Company or any of its subsidiaries. 
 In addition, we have
participated in the preparation of the Registration Statement (SEC File #                    ) covering the sale of the Purchase Shares, the
Commitment Shares and the Expense Shares including the prospectus dated                     , contained therein and in conferences with
officers and other representatives of the Company (including the Company’s independent auditors) during which the contents of the Registration Statement and related matters were discussed and reviewed and, although we are not passing upon and
do not assume any responsibility, explicitly or implicitly, for the accuracy, completeness or fairness of the statements contained in the Registration Statement, on the basis of the information that was developed in the course of the performance of
the services referred to above, 







 
considered in the light of our understanding of the applicable law, nothing came to our attention that caused us to believe that the Registration Statement (other than the financial statements,
notes, and schedules thereto and the other information of a financial, statistical or accounting nature included therein, as to which we express no belief), as of their dates, contained any untrue statement of a material fact or omitted to state any
material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading (it being understood that we express no opinion or view with respect to
laws, rules, proceedings, actions, suits, claims investigations, decrees, authorizations, consents, approvals, orders, regulations or filings related to, or any rights or obligations of the Company or any Subsidiary with respect to, matters relating
to patents, trademarks, service marks, trade names, service names, trade secrets or copyrights, or otherwise with respect to any other matter regarding proprietary information or intellectual property, or with respect to any matters regarding
regulations under the U.S. Food and Drug Administration). 







 EXHIBIT B 

FORM OF OFFICER’S CERTIFICATE 
 This Officer’s Certificate (“Certificate”) is being delivered pursuant to Section 8(e) of that certain Purchase Agreement dated as of
                    , (“Purchase Agreement”), by and between MARINA BIOTECH, INC., a Delaware corporation (the
“Company”), and LINCOLN PARK CAPITAL FUND, LLC (the “Investor”). Terms used herein and not otherwise defined shall have the meanings ascribed to them in the Purchase Agreement. 

The undersigned,
                    ,
                     of the Company, hereby certifies as follows: 

1. I am the
                             of the Company and make the statements contained in this Certificate;

 2. The representations and warranties of the Company are true and correct in all material respects (except to
the extent that any of such representations and warranties is already qualified as to materiality in Section 4 of the Purchase Agreement, in which case, such representations and warranties are true and correct without further qualification) as
of the date when made and as of the Commencement Date as though made at that time (except for representations and warranties that speak as of a specific date); 
 3. The Company has performed, satisfied and complied in all material respects with covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by
the Company at or prior to the Commencement Date. 
 4. The Company has not taken any steps, and does not
currently expect to take any steps, to seek protection pursuant to any Bankruptcy Law nor does the Company or any of its Subsidiaries have any knowledge or reason to believe that its creditors intend to initiate involuntary bankruptcy or insolvency
proceedings. The Company is financially solvent and is generally able to pay its debts as they become due. 
 IN WITNESS
WHEREOF, I have hereunder signed my name on this          day of                     .

  

	
	  
	Name:
	Title:


 The undersigned as Secretary of MARINA BIOTECH, INC., a Delaware corporation, hereby
certifies that                      is the duly elected, appointed, qualified and acting
                     of
                     and that the signature appearing above is his genuine signature. 

 

	
	  
	Secretary









 EXHIBIT C 

FORM OF COMPANY RESOLUTIONS 
 FOR SIGNING PURCHASE AGREEMENT 
 WHEREAS, there has been presented to the
Board of Directors of MARINA BIOTECH, INC., a Delaware corporation (the “Corporation”) a draft of the Purchase Agreement (the “Purchase Agreement”) by and between the Corporation and Lincoln Park Capital Fund, LLC (“Lincoln
Park”), providing for the purchase by Lincoln Park of up to Fifteen Million Dollars ($15,000,000) of the Corporation’s common stock, $.006 par value per share (the “Common Stock”); and 

WHEREAS, after consideration and review of the Purchase Agreement, the documents attached thereto and other factors deemed relevant by
the Board of Directors, the Board of Directors has determined that it is advisable and in the best interests of the Corporation to engage in the transactions contemplated by the Purchase Agreement, including, but not limited to, the issuance of
50,000 shares of Common Stock to Lincoln Park as an expense reimbursement (the “Expense Shares”), the issuance of 1,452,785 shares of Common Stock to Lincoln Park as an initial commitment fee (the “Initial Commitment Shares”) and
the sale of up to $15,000,000 worth of shares of Common Stock to Lincoln Park (the “Purchase Shares”). 

Transaction Documents 
 NOW, THEREFORE, BE IT RESOLVED, that the transactions described in the Purchase Agreement are hereby approved and each of Philip C. Ranker and J. Michael French (the “Authorized Officers”) are
severally authorized to execute and deliver the Purchase Agreement on behalf of the Company, and any other agreements or documents contemplated thereby including, without limitation, a registration rights agreement (the “Registration Rights
Agreement”) providing for the registration of the shares of the Company’s Common Stock issuable in respect of the Purchase Agreement on behalf of the Corporation, with such amendments, changes, additions and deletions as the Authorized
Officers may deem to be appropriate and approve on behalf of, the Corporation, such approval to be conclusively evidenced by the signature of an Authorized Officer thereon; and 

FURTHER RESOLVED, that the terms and provisions of the Registration Rights Agreement by and among the Corporation and Lincoln Park, a
draft of which has been provided to the Board, are hereby approved and the Authorized Officers are authorized to execute and deliver the Registration Rights Agreement on behalf of the Company, with such amendments, changes, additions and deletions
as the Authorized Officer may deem appropriate and approve on behalf of, the Corporation, such approval to be conclusively evidenced by the signature of an Authorized Officer thereon; and 

FURTHER RESOLVED, that the terms and provisions of the Form of Irrevocable Transfer Agent Instructions (the “Instructions”), a
draft of which has been provided to the Board, are hereby approved and the Authorized Officers are authorized to execute and deliver the Instructions on behalf of the Company, with such amendments, changes, additions and deletions as the Authorized
Officers may deem appropriate and approve on behalf of, the Corporation, such approval to be conclusively evidenced by the signature of an Authorized Officer thereon; and 
 Issuance of Common Stock 
 FURTHER RESOLVED, that the Corporation is
hereby authorized to issue to Lincoln Park 50,000 shares of Common Stock as Expense Shares, and the Expense Shares shall be duly authorized, validly issued, fully paid and nonassessable with no personal liability attaching to the ownership thereof;
and 







 FURTHER RESOLVED, that the Corporation is hereby authorized to issue to Lincoln Park
1,452,785 shares of Common Stock as Initial Commitment Shares pursuant to the Purchase Agreement, and the Initial Commitment Shares shall be duly authorized, validly issued, fully paid and nonassessable with no personal liability attaching to the
ownership thereof; and 
 FURTHER RESOLVED, that the Corporation is hereby authorized to issue to Lincoln Park up to 17,779,000
shares of Common Stock as the Purchase Shares and upon issuance of the Purchase Shares pursuant to the Purchase Agreement, the Purchase Shares will be duly authorized, validly issued, fully paid and nonassessable with no personal liability attaching
to the ownership thereof; and 
 FURTHER RESOLVED, that the Corporation shall initially reserve 19,000,000 shares of Common
Stock for issuance as Purchase Shares under the Purchase Agreement; and 
 FURTHER RESOLVED, that the Corporation is hereby
authorized to issue 1,221,000 shares of Common Stock (subject to equitable adjustment for any reorganization, recapitalization, non-cash dividend, stock split or other similar transaction) in connection with the purchase of Purchase Shares (the
“Additional Commitment Shares”) in accordance with the terms of the Purchase Agreement and that, upon issuance of the Additional Commitment Shares pursuant to the Purchase Agreement, the Additional Commitment Shares will be duly
authorized, validly issued, fully paid and nonassessable with no personal liability attaching to the ownership thereof; and 

FURTHER RESOLVED, that the Corporation shall initially reserve 1,221,000 shares of Common Stock (subject to equitable adjustment for any
reorganization, recapitalization, non-cash dividend, stock split or other similar transaction) for issuance as Additional Commitment Shares under the Purchase Agreement; and 
 Approval of Actions 
 FURTHER RESOLVED, that, without limiting the
foregoing, the Authorized Officers are, and each of them hereby is, authorized and directed to proceed on behalf of the Corporation and to take all such steps as deemed necessary or appropriate, with the advice and assistance of counsel, to cause
the Corporation to consummate the agreements referred to herein and to perform its obligations under such agreements; and 

FURTHER RESOLVED, that the Authorized Officers be, and each of them hereby is, authorized, empowered and directed on behalf of and in the
name of the Corporation, to take or cause to be taken all such further actions and to execute and deliver or cause to be executed and delivered all such further agreements, amendments, documents, certificates, reports, schedules, applications,
notices, letters and undertakings and to incur and pay all such fees and expenses as in their judgment shall be necessary, proper or desirable to carry into effect the purpose and intent of any and all of the foregoing resolutions, and that all
actions heretofore taken by any officer or director of the Corporation in connection with the transactions contemplated by the agreements described herein are hereby approved, ratified and confirmed in all respects. 







 EXHIBIT D 

FORM OF SECRETARY’S CERTIFICATE 
 This Secretary’s Certificate (“Certificate”) is being delivered pursuant to Section 7(k) of that certain Purchase Agreement dated as of
                    , (“Purchase Agreement”), by and between MARINA BIOTECH, INC., a Delaware corporation (the
“Company”) and LINCOLN PARK CAPITAL FUND, LLC (the “Investor”), pursuant to which the Company may sell to the Investor up to Fifteen Million Dollars ($15,000,000) of the Company’s Common Stock, $.006 par value per
share (the “Common Stock”). Terms used herein and not otherwise defined shall have the meanings ascribed to them in the Purchase Agreement. 
 The undersigned,                     , Secretary of the Company, hereby certifies as follows:

 1. I am the Secretary of the Company and make the statements contained in this Secretary’s Certificate.

 2. Attached hereto as Exhibit A and Exhibit B are true, correct and complete copies of the
Company’s bylaws (“Bylaws”) and Certificate of Incorporation (“Articles”), in each case, as amended through the date hereof, and no action has been taken by the Company, its directors, officers or shareholders, in
contemplation of the filing of any further amendment relating to or affecting the Bylaws or Articles. 
 3.
Attached hereto as Exhibit C are true, correct and complete copies of the resolutions duly adopted by the Board of Directors of the Company on
                    , at which a quorum was present and acting throughout. Such resolutions have not been amended, modified or rescinded and
remain in full force and effect and such resolutions are the only resolutions adopted by the Company’s Board of Directors, or any committee thereof, or the shareholders of the Company relating to or affecting (i) the entering into and
performance of the Purchase Agreement, or the issuance, offering and sale of the Purchase Shares and the Commitment Shares and (ii) and the performance of the Company of its obligation under the Transaction Documents as contemplated therein.

 4. As of the date hereof, the authorized, issued and reserved capital stock of the Company is as set forth on
Exhibit D hereto. 
 IN WITNESS WHEREOF, I have hereunder signed my name on this
       day of                     . 

 

	
	  
	Secretary


 The undersigned as
                     of MARINA BIOTECH, INC., a Delaware corporation, hereby certifies that
                     is the duly elected, appointed, qualified and acting Secretary of
                        , and that the signature appearing above is his genuine signature. 

 

	
	  









 EXHIBIT E 

FORM OF LETTER TO THE TRANSFER AGENT FOR THE ISSUANCE OF THE INITIAL 

COMMITMENT SHARES AT SIGNING OF THE PURCHASE AGREEMENT 
 [COMPANY LETTERHEAD] 
 [DATE] 

 

	
	[TRANSFER AGENT]
	  
	  
	  

 Re: Issuance of Common Shares to Lincoln Park Capital Fund, LLC 
 Dear                     , 
 On behalf of MARINA BIOTECH, INC., (the “Company”), you are hereby instructed to issue as soon as possible 1,452,785 shares of our common stock as Initial Commitment Shares
in the name of Lincoln Park Capital Fund, LLC. The share certificate should be dated [DATE OF THE PURCHASE AGREEMENT]. I have included a true and correct copy of the resolutions adopted by the Board of Directors of the Company adopting
resolutions approving the issuance of these shares. The shares should be issued subject to the following restrictive legend: 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE
STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR APPLICABLE STATE SECURITIES LAWS, UNLESS SOLD PURSUANT TO: (1) RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (2) AN OPINION OF HOLDER’S COUNSEL, IN A CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID
ACT OR APPLICABLE STATE SECURITIES LAWS. 
 The share certificate should be sent as soon as possible via overnight mail to the
following address: 
 Lincoln Park Capital Fund, LLC 
 440 North Wells, Suite 620 
 Chicago, IL 60654 

Attention: Josh Scheinfeld/Jonathan Cope 







 Thank you very much for your help. Please call me at
                     if you have any questions or need anything further. 

 

			
	MARINA BIOTECH, INC.
		
	BY:	 	 
		 	[name]
		 	[title]